We help communities to created a custom knowledge base(still being refined)
A debilitating form of dementia, this progressive and irreversible neurode- generative disease results in the development of protein plaques and tangles that damages neurons and interfere with neural signaling, ultimately affecting memory and other important cognitive skills.
Click here to view original web page at www.globenewswire.com
TORONTO and CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, continues to further develop antibody candidates that have shown selectivity […]
Click here to view original web page at www.biospace.com
HEIDELBERG, Germany, October 28, 2019 / B3C newswire / — BioMed X announced today the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease. BioMed X received a milestone payment and the results of the project were transferred to […]
Click here to view original web page at www.b3cnewswire.com
HEIDELBERG, Germany, October 28, 2019 / B3C newswire / — BioMed X announced today the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease. BioMed X received a milestone payment and the results of the project were transferred to […]
Click here to view original web page at www.forbes.com
Getty Alzheimer’s disease and type 2 diabetes could be linked in ways we’re only beginning understand, according to scientists presenting the latest research findings at Neuroscience 2019 , the annual meeting of the Society for Neuroscience. Untangling the connection could lead to earlier Alzheimer’s diagnosis and better treatments for […]
Click here to view original web page at www.krqe.com
Albuquerque Neuroscience, Inc. is a local, family-owned clinic that contributes to the development of new treatment for psychiatric illnesses. The clinic is currently conducting a clinical trial on participants with mild to moderate Alzheimer’s disease. Clinical research coordinator Anderson Riddle explains more about this clinical trial. The goal of […]
Click here to view original web page at pipelinereview.com
— Lead compound is an oral small molecule inhibitor of tau aggregation — — The company expects clinical testing to begin in 2021 — CHICAGO, IL, USA I October 22, 2019 I Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) […]
Click here to view original web page at www.businesswire.com
CHICAGO–( BUSINESS WIRE )–Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, presented preclinical data today showing that its orally active, small molecule compound inhibits the earliest steps in the toxic tau aggregation cascade that leads to […]
Click here to view original web page at finance.yahoo.com
CHICAGO–(BUSINESS WIRE)– — Lead compound is an oral small molecule inhibitor of tau aggregation — — The company expects clinical testing to begin in 2021 — Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, presented preclinical […]
Click here to view original web page at www.globenewswire.com
NEW HAVEN, Conn., Oct. 14, 2019 (GLOBE NEWSWIRE) — RxGen, a preclinical translational research company, will be presenting a poster highlighting its progress in advancing preclinical models of Alzheimer’s disease (AD) to better predict clinical outcomes during the Society for Neuroscience (SfN) 49 th Annual Meeting in Chicago from […]
